# Implementation Strategies to Promote Equitable Dissemination of Long-Acting injectable PrEP to Black/Latino MSM and Transgender Women in Los Angeles

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $245,539

## Abstract

PROJECT ABSTRACT: HIV disproportionately affects Black and Latino men who have sex with men
and transgender women (BLMSM/TGW). These populations would greatly benefit from early access
to new HIV prevention tools. Recently, the Food and Drug Administration approved Apretude (an
extended-release injectable form of cabotegravir) for use as long-acting injectable pre-exposure
prophylaxis (LAI PrEP) to reduce the risk of acquiring HIV through sex. The equitable dissemination
of LAI PrEP to BLMSM/TGW can help decrease new HIV infections in these populations.
Unfortunately, historically these populations have lagged behind more privileged, well-resourced,
White gay men in receiving information about the newest HIV prevention options and the means of
accessing them to benefit from early adoption. As such, the goal of this project is to work within the
“Exploration and Preparation” phases of the Exploration, Preparation, Implementation, Sustainment
(EPIS) implementation framework to implement strategies to promote the equitable dissemination of
LAI PrEP among BLMSM/TGW in Los Angeles County (LAC). This project focuses on the Prevent
pillar of the national Ending the HIV Epidemic initiative and aligns with LAC’s EHE plan to facilitate
PrEP scale up efforts and reduce barriers to access and continuation. The project has three specific
aims. Aims 1 and 2 are to increase awareness and knowledge of, and trust and confidence in, LAI
PrEP as a new HIV prevention option among BLMSM/TGW and providers serving them. Aim 3 is to
develop a LAI PrEP strategic messaging guide to support ongoing diffusion of LAI PrEP information
by the LAC Public Health Department’s Division of HIV and STD Programs and BLMSM/TGW service
providers to facilitate greater community awareness and stimulate community discourse about the
use of this new HIV prevention tool among BLMSM/TGW in LAC. To achieve aims 1 and 2, we will
use a community-engaged approach to develop a series of informational/ educational community
workshops (n = 7) that prioritize and preemptively build service provider and consumer awareness,
knowledge, and confidence in LAI PrEP as an acceptable HIV prevention option for BLMSM/TGW in
LAC. To complete aim 3, we will conduct focus groups (n = 6) with BLMSM/TGW to inform the
development of a LAI PrEP strategic messaging guide of community-developed, culturally appropriate
messaging. The expected outcome of the project is creating greater community awareness, trust, and
confidence in LAI PrEP as a HIV prevention option for BLMSM/TGW among both consumers and
service providers. The anticipated impact of the project is a more equitable dissemination and
implementation of LAI PrEP among at-risk BLMSM/TGW heavily burdened by HIV in LAC.

## Key facts

- **NIH application ID:** 10602050
- **Project number:** 3P30MH058107-26S3
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Ronald Andrew Brooks
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $245,539
- **Award type:** 3
- **Project period:** 1997-09-30 → 2026-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10602050

## Citation

> US National Institutes of Health, RePORTER application 10602050, Implementation Strategies to Promote Equitable Dissemination of Long-Acting injectable PrEP to Black/Latino MSM and Transgender Women in Los Angeles (3P30MH058107-26S3). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10602050. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*